Notice concerning Discussions between Meiji Seika Pharma and Arcalis, Regarding the Production and Supply of “ARCT-154” for Replicon Vaccine for COVID-19
ARCALIS,Inc. (Headquarters: Kashiwa, Chiba, Japan; President & CEO: Tomoyuki Fujisawa; hereinafter referred to as “ARCALIS”) announced today that ARCALIS has entered into discussions with Meiji Seika Pharma Inc. (Head Office: Chuo-ku, Tokyo; President: Daikichiro Kobayashi; hereinafter referred to as “Meiji Seika Pharma”) regarding the production and supply in Japan of replicon vaccine ARCT-154, a replicon vaccine (next-generation mRNA vaccine) that is potentially useful against mutant strains such as Omicron strain, developed by Arcturus Therapeutics Inc. (Head Office: San Diego, U.S.A.; President & CEO: Joseph E. Payne).
Production is planned to take place at the Minamisoma Plant in Fukushima Prefecture, which is currently under construction by ARCALIS.
Details will be disclosed promptly after the conclusion of the agreement.
Arcalis Press Release in English PDF